Navigation Links
PDL BioPharma Announces First Quarter 2012 Financial Results
Date:5/3/2012

Convertible Senior Notes due 2015 (May 2015 Notes), non-GAAP net income for the first quarter of 2012 was $41.8 million, or $0.30 per diluted share, compared to non-GAAP net income of $44.5 million, or $0.25 per diluted share for the same period of 2011.

Net cash provided by operating activities in the first quarter of 2012 was $17.9 million, compared with net cash used in operating activities of $13.2 million for the first quarter of 2011. At March 31, 2012, PDL had cash, cash equivalents and investments of $192.5 million, compared with $227.9 million at December 31, 2011. 

Recent Developments2012 Dividends On January 18, 2012, PDL's Board of Directors declared regular quarterly dividends of $0.15 per share of common stock, payable on March 14, June 14, September 14 and December 14 of 2012 to stockholders of record on March 7, June 7, September 7 and December 7 of 2012, the record dates for each of the dividend payments, respectively. On March 14, 2012, PDL paid the first quarterly dividend to stockholders of record totaling $21 million using earnings generated in the first quarter of 2012 and cash on hand.

Exchange and Retirement of Convertible NotesIn January and February 2012, PDL completed public and privately negotiated exchange transactions whereby the Company exchanged and subsequently retired $179.0 million aggregate principal amount, representing over 99 percent of the 2.875% Convertible Senior Notes due February 15, 2015 (February 2015 Notes), for $179.0 million aggregate principal amount of new 2.875% Series 2012 Notes, and by doing so, eliminated 27.8 million shares of potential dilution to our stock holders.  In the public exchanges, PDL made one-time cash payments of $5.00 for each $1,000 principal amount tendered for a total cash incentive payment of $0.8 million. As of March 31, 2012, $1.0 million of the February 2015 Notes and $179.0 million
'/>"/>

SOURCE PDL BioPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Inspiration Biopharmaceuticals Announces Filing of Biologics License Application (BLA) for IB1001, a Recombinant Factor IX Product for People with Hemophilia B
2. Genesis Biopharma Announces Proposed Public Offering of Common Stock and Warrants
3. Laureate Biopharma Names James D. Utterback to Board of Directors
4. Enox Biopharma, Inc. Will Present at IN360 Investment in Innovation Conference
5. PDL BioPharma Announces Fourth Quarter and Full Year 2011 Financial Results
6. Laureate Biopharma Appoints Les Mintzmyer, Vice President, Operations
7. Galien Foundation Announces 2012 Awards Program For Best Biopharmaceutical Products and Best Medical Technology
8. Sigma-Aldrich to Acquire BioReliance; Extending Its Reach into Biopharmaceutical Testing and Services
9. HealthCare Institute of New Jersey Releases 2011 Biopharmaceutical and Medical Technology Economic Impact Data
10. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
11. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... May 22, 2015 Baylor Research Institute (BRI) ... Translational Genomics Research Institute (TGen) in Phoenix, ... on accelerating early detection and treatments for patients with a ... institutions will lead to new clinical trials and access to ... the gap from bench to bedside across Baylor Scott ...
(Date:5/21/2015)... 21, 2015  Susan Hedstrom, Executive Director of ... organization dedicated to supporting research to advance the ... today that FPWR has received the organization,s largest ... contributed $1 million in support of the ... "Our gift signifies our ...
(Date:5/21/2015)... , May 21, 2015 ... inner feelings - and those of others. Being able ... senses. Analyze and read people to anticipate their thoughts ... your deepest emotions and feelings to create unique abstract ... of responsive games. Get inside a first-person-shooter as it ...
(Date:5/21/2015)... As part of its philanthropic partnership with Banner ... funded a $3.25 million project to relocate and equip ... up-to-date features and technology. , The new pharmacy is ... members will begin moving from the current location to ... , The current pharmacy has been using a ...
Breaking Biology Technology:Precision Medicine Collaboration to Increase Options for Cancer Patients 2Precision Medicine Collaboration to Increase Options for Cancer Patients 3Precision Medicine Collaboration to Increase Options for Cancer Patients 4The Foundation for Prader-Willi Research Receives $1M Contribution in Support of Clinical Initiatives 25 Days to Meet ARGUS - The World's First Contactless Emotions Scanner 2Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 2Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 3
... Second Round of Funding Supports Commercialization of Recently FDA-cleared ... Pathwork(R) Tissue of ... a,molecular diagnostics company focused on oncology, announced the closing,today of ... the heels of FDA,s clearance for the Pathwork(R) Tissue of ...
... Symbol: MS, EDMONTON, Sept. 4 /PRNewswire-FirstCall/ - ... the treatment of multiple sclerosis (MS), today,announced that ... United States,has granted fast track designation for the ... secondary progressive MS (SPMS). Dirucotide,(MBP8298) is currently being ...
... revenue from available ... - Revenue potential from manufacturing alliances, including the alliance, with Hospira, could amount to ... ... 4 Human Genome,Sciences, Inc. (Nasdaq: HGSI ) today announced that it has entered ...
Cached Biology Technology:Pathwork Diagnostics Closes $20M Financing 2BioMS Medical's lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA 2BioMS Medical's lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA 3BioMS Medical's lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA 4Human Genome Sciences Announces Process Development and Manufacturing Alliance With Hospira 2Human Genome Sciences Announces Process Development and Manufacturing Alliance With Hospira 3Human Genome Sciences Announces Process Development and Manufacturing Alliance With Hospira 4
(Date:4/14/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market, announces that its Wocket® smart ... Design Awards under the category  ,Product Design – Technology,. ... are part of a global multi-disciplinary awards program. The ... marketplace, industry and judging panel. Winners will be announced ...
(Date:4/13/2015)... CHICAGO , April 13, 2015  higi, a ... with ways to more fully engage with their communities ... its industry-leading, privacy protected and secure API.  ... API enables the most accessible, affordable, and convenient vehicle ... The API will ...
(Date:4/9/2015)... April 9, 2015 Synaptics Inc. (NASDAQ: SYNA ... today that it will report financial results for the ... 2015, after the close of market. The company will ... at 2:00 p.m. PT (5:00 p.m. ET), during which ... participate on the live call, analysts and investors should ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3Synaptics to Report Third Quarter Results on April 23 2
... release is available in German . , It ... the fate of individual cells during the early development of ... team of molecular biologists led by Pia Aanstad of the ... accounts for the interpretation of the concentration of the signaling ...
... patient,s body, stem cells intended to treat or cure ... they are no longer under the control of the ... solve this problem, according to a perspective article from ... a recent issue of the journal Cell Stem ...
... the time of the Babylonians to the Incas, terracing ... and hilly croplands. Designing terrace layouts can be time ... are developing a Web-based program that will design multiple ... will help farm experts choose the most efficient and ...
Cached Biology News:Why the thumb of the right hand is on the left hand side 2Gene therapy could expand stem cells' promise 2Web-based program designs more efficient farm terrace layouts 2